Treats partial-onset seizures. ANDA 215332, held by Aucta. Oxcarbazepine.
As of Nov 16, 2026, ANDA 215332 (Oxcarbazepine), held by Aucta, was first approved by FDA on Nov 30, 2022, with 3 approved supplements and 0 published complete response letters.
Oxcarbazepine oral suspension is indicated for use as monotherapy or adjunctive therapy in the treatment of partial-onset seizures in adults and as monotherapy in the treatment of partial-onset seizures in pediatric patients aged 4 years and above, and as adjunctive therapy in pediatric patients aged 2 years and above with partial- onset seizures. Oxcarbazepine oral suspension is indicated for: Adults: Monotherapy or adjunctive therapy in the treatment of partial-onset seizures Pediatrics: - Monotherapy in the treatment of partial-onset seizures in children 4-16 years - Adjunctive therapy in the treatment of partial-onset seizures in children 2-16 years
| Date | Submission | Status | Documents |
|---|---|---|---|
| Nov 30, 2022 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Oxcarbazepine300MG/5ML · suspension;oral | Oxcarbazepine | Rx |
| Jun 2, 2026 | Supplement 6Labeling · Standard review | Approved | None posted |
| Sep 16, 2025 | Supplement 5Labeling · Standard review | Approved | None posted |
| Mar 14, 2023 | Supplement 1Labeling · Standard review | Approved | None posted |
| Nov 30, 2022 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters